赛诺医疗(688108) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥42,499,145.99, a decrease of 56.93% compared to the same period last year[5] - The net profit attributable to shareholders was -¥29,591,522.07, representing a decline of 267.44% year-on-year[5] - The basic earnings per share for the year-to-date period was -¥0.27, a decrease of 325.00% year-on-year[6] - The company reported a net loss of RMB 22,596,021.42 for the period, compared to a profit of RMB 88,537,713.00 in the previous year[17] - Total operating revenue for the first three quarters of 2021 was ¥121.13 million, a decrease of 56.0% compared to ¥275.12 million in the same period of 2020[20] - Net profit for the first three quarters of 2021 was a loss of ¥112.53 million, compared to a profit of ¥49.03 million in the same period of 2020[21] - The total comprehensive income for the first three quarters of 2021 was a loss of ¥113.22 million, compared to a gain of ¥48.25 million in 2020[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,097,759,942.46, down 9.83% from the end of the previous year[6] - As of September 30, 2021, the total assets of the company amounted to RMB 1,097,759,942.46, a decrease from RMB 1,217,497,750.16 as of December 31, 2020, representing a decline of approximately 9.8%[16] - The company's total current assets decreased to RMB 465,173,524.12 from RMB 723,433,818.99, reflecting a reduction of about 35.7%[15] - The total liabilities decreased to RMB 133,111,270.82 from RMB 139,630,293.64, a decline of about 4.0%[17] - The company's equity attributable to shareholders decreased to RMB 948,188,001.12 from RMB 1,077,867,456.52, a drop of approximately 11.9%[17] - Non-current liabilities increased to 47,454,613.25 RMB from 89,477,678.11 RMB, primarily due to the implementation of the new leasing standard[30] Cash Flow - The net cash flow from operating activities for the year-to-date period was -¥65,253,791.21, a decline of 201.62% compared to the previous year[6] - Operating cash flow for the first three quarters of 2021 was a net outflow of ¥65.25 million, contrasting with a net inflow of ¥64.21 million in 2020[25] - The net cash flow from financing activities was -41,040,839.56 RMB, indicating a significant outflow due to debt repayment and dividend distribution[26] - The cash and cash equivalents at the end of the period decreased to 280,526,833.35 RMB from 544,664,800.71 RMB at the beginning of the period, reflecting a net decrease of 264,137,967.36 RMB[26] Research and Development - Research and development expenses totaled ¥38,332,118.46, an increase of 3.70% compared to the same period last year, accounting for 90.20% of operating revenue[6] - Research and development expenses increased significantly to ¥108.74 million in 2021 from ¥74.45 million in 2020, marking a rise of 46.0%[20] Inventory and Other Assets - The company's inventory increased to RMB 79,088,470.52 from RMB 64,748,983.65, reflecting a rise of approximately 22.1%[16] - The company has ongoing investments in long-term equity amounting to RMB 25,573,665.32[16] - The company has a total of 82,067,762.90 RMB in intangible assets, which reflects ongoing investments in technology and product development[29] - The company’s other non-current assets totaled 6,338,644.14 RMB, indicating a stable asset base[29] Shareholder Information - The total equity attributable to shareholders was ¥948,188,001.12, down 12.03% from the previous year[6] - The company reported a total of 11,099 common shareholders at the end of the reporting period[13]